JP2007506748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506748A5 JP2007506748A5 JP2006528110A JP2006528110A JP2007506748A5 JP 2007506748 A5 JP2007506748 A5 JP 2007506748A5 JP 2006528110 A JP2006528110 A JP 2006528110A JP 2006528110 A JP2006528110 A JP 2006528110A JP 2007506748 A5 JP2007506748 A5 JP 2007506748A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- methyl
- methoxy
- dihydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 206010003119 arrhythmia Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 230000005764 inhibitory process Effects 0.000 claims 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 2
- 206010003662 Atrial flutter Diseases 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- WNSFBSVZSFGWKG-UHFFFAOYSA-N 2-cyclopropyl-6-methoxy-4-phenyl-3-(1,3-thiazol-2-yl)isoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C2CC2)C=2C=3SC=CN=3)=O)C=1C=2C1=CC=CC=C1 WNSFBSVZSFGWKG-UHFFFAOYSA-N 0.000 claims 1
- QPSHMPFUHZJDOG-UHFFFAOYSA-N 4-(3-fluorophenyl)-6-methoxy-2-methyl-3-(pyrrolidine-1-carbonyl)isoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C(=O)N3CCCC3)=O)C=1C=2C1=CC=CC(F)=C1 QPSHMPFUHZJDOG-UHFFFAOYSA-N 0.000 claims 1
- BPWTXMARXPIAPN-UHFFFAOYSA-N 4-(3-fluorophenyl)-6-methoxy-n,n,2-trimethyl-1-oxoisoquinoline-3-carboxamide Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C(=O)N(C)C)=O)C=1C=2C1=CC=CC(F)=C1 BPWTXMARXPIAPN-UHFFFAOYSA-N 0.000 claims 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 1
- HQHWFQBVHGZPDU-UHFFFAOYSA-N 6-methoxy-2-methyl-4-phenyl-3-pyridin-2-ylisoquinolin-1-one Chemical compound C=1C(OC)=CC=C(C(N(C)C=2C=3N=CC=CC=3)=O)C=1C=2C1=CC=CC=C1 HQHWFQBVHGZPDU-UHFFFAOYSA-N 0.000 claims 1
- LVYBSQBIEGOECD-UHFFFAOYSA-N 7-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylic acid Chemical compound OC(=O)C=1N(C)C(=O)C2=CC(OC)=CC=C2C=1C1=CC=CC=C1 LVYBSQBIEGOECD-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 claims 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229940127449 Integrin Receptor Antagonists Drugs 0.000 claims 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 claims 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 claims 1
- 108091007262 P2T receptors Proteins 0.000 claims 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- -1 factor Xa inhibitors Substances 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- JHHCUIOLGXFAFI-UHFFFAOYSA-N methyl 4-(3-fluorophenyl)-6-methoxy-2-methyl-1-oxoisoquinoline-3-carboxylate Chemical compound C12=CC(OC)=CC=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC(F)=C1 JHHCUIOLGXFAFI-UHFFFAOYSA-N 0.000 claims 1
- CUTKKQAWWOLGDB-UHFFFAOYSA-N methyl 6-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylate Chemical compound C12=CC(OC)=CC=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC=C1 CUTKKQAWWOLGDB-UHFFFAOYSA-N 0.000 claims 1
- OAHAJCKNSCXKLU-UHFFFAOYSA-N methyl 7-methoxy-2-methyl-1-oxo-4-phenylisoquinoline-3-carboxylate Chemical compound C12=CC=C(OC)C=C2C(=O)N(C)C(C(=O)OC)=C1C1=CC=CC=C1 OAHAJCKNSCXKLU-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 150000008143 steroidal glycosides Chemical class 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 229960005001 ticlopidine Drugs 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50513803P | 2003-09-23 | 2003-09-23 | |
| US60/505,138 | 2003-09-23 | ||
| PCT/US2004/030944 WO2005030727A1 (en) | 2003-09-23 | 2004-09-22 | Isoquinolinone potassium channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007506748A JP2007506748A (ja) | 2007-03-22 |
| JP2007506748A5 true JP2007506748A5 (enExample) | 2007-08-02 |
| JP4719152B2 JP4719152B2 (ja) | 2011-07-06 |
Family
ID=34392983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006528110A Expired - Fee Related JP4719152B2 (ja) | 2003-09-23 | 2004-09-22 | イソキノリノンカリウムチャネル阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7781457B2 (enExample) |
| EP (1) | EP1667977A4 (enExample) |
| JP (1) | JP4719152B2 (enExample) |
| CN (1) | CN1856473A (enExample) |
| AU (1) | AU2004276267B2 (enExample) |
| CA (1) | CA2539541C (enExample) |
| WO (1) | WO2005030727A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004276268B2 (en) * | 2003-09-23 | 2009-01-29 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
| JP4718467B2 (ja) * | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノンカリウムチャネル阻害剤 |
| AU2004276238B2 (en) * | 2003-09-23 | 2010-10-28 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| CA2539853C (en) * | 2003-09-23 | 2011-04-19 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| CN1993347A (zh) | 2004-07-29 | 2007-07-04 | 默克公司 | 钾通道抑制剂 |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
| WO2007121453A2 (en) * | 2006-04-17 | 2007-10-25 | The Regents Of The University Of California | 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents |
| DE102006019589A1 (de) * | 2006-04-27 | 2007-10-31 | Sanofi-Aventis Deutschland Gmbh | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
| CN101636154B (zh) * | 2006-04-27 | 2011-12-14 | 塞诺菲-安万特德国有限公司 | Task-1和task-3离子通道抑制剂 |
| CA2659251C (en) | 2006-07-10 | 2016-06-14 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| BRPI0806371A2 (pt) | 2007-01-22 | 2011-09-13 | Gtx Inc | agentes ligação de receptor nuclear |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US8563580B2 (en) | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| EP2344481B9 (en) * | 2008-09-23 | 2014-12-31 | Georgetown University | Viral and fungal inhibitors |
| EP2816038B8 (en) | 2009-08-24 | 2019-12-25 | Lumiphore, Inc. | Hopo chelators |
| WO2012028300A1 (en) * | 2010-09-01 | 2012-03-08 | Grünenthal GmbH | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators |
| CN103864684A (zh) * | 2012-12-07 | 2014-06-18 | 天津科技大学 | 一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用 |
| US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE124408T1 (de) * | 1990-10-16 | 1995-07-15 | Takeda Chemical Industries Ltd | Heterozyklische aminderivate, deren herstellung und deren verwendung. |
| TW241258B (enExample) | 1992-04-15 | 1995-02-21 | Takeda Pharm Industry Co Ltd | |
| DE69315920T2 (de) * | 1992-09-04 | 1998-06-10 | Takeda Chemical Industries Ltd | Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung |
| TW263498B (enExample) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| WO1998038168A1 (en) * | 1997-02-27 | 1998-09-03 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
| JPH10298164A (ja) * | 1997-02-27 | 1998-11-10 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体、その製法及びその合成中間体 |
| JP2000072751A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体 |
| US6444685B1 (en) * | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| AU1296902A (en) * | 2000-09-20 | 2002-04-02 | Merck & Co Inc | Isoquinolinone potassium channel inhibitors |
| PL364221A1 (en) | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
| CA2476162A1 (en) * | 2002-02-13 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| AU2004276268B2 (en) * | 2003-09-23 | 2009-01-29 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
| CA2539853C (en) * | 2003-09-23 | 2011-04-19 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| AU2004276238B2 (en) * | 2003-09-23 | 2010-10-28 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| JP4718467B2 (ja) * | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリノンカリウムチャネル阻害剤 |
-
2004
- 2004-09-22 US US10/572,343 patent/US7781457B2/en not_active Expired - Fee Related
- 2004-09-22 EP EP04788883A patent/EP1667977A4/en not_active Withdrawn
- 2004-09-22 CA CA2539541A patent/CA2539541C/en not_active Expired - Fee Related
- 2004-09-22 JP JP2006528110A patent/JP4719152B2/ja not_active Expired - Fee Related
- 2004-09-22 AU AU2004276267A patent/AU2004276267B2/en not_active Ceased
- 2004-09-22 CN CNA2004800273785A patent/CN1856473A/zh active Pending
- 2004-09-22 WO PCT/US2004/030944 patent/WO2005030727A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506748A5 (enExample) | ||
| JP2007516218A5 (enExample) | ||
| JP2007506742A5 (enExample) | ||
| Thompson et al. | Perioperative cardiac arrhythmias | |
| WO2008073392A3 (en) | Compositions and methods for cardiac tissue protection and regeneration | |
| CA2539814A1 (en) | Isoquinolinone potassium channel inhibitors | |
| CN102665713A (zh) | 治疗心房颤动的方法 | |
| DK1235831T3 (da) | Nye oxabispidinforbindelser, der er anvendelige til behandling af hjertearytmier | |
| CA2539541A1 (en) | Isoquinolinone potassium channel inhibitors | |
| JPH07506354A (ja) | 抗虚血薬剤 | |
| HK1052170A1 (zh) | 新型化合物抑制因子xa活度 | |
| Fiala et al. | Termination of long‐lasting persistent versus short‐lasting persistent and paroxysmal atrial fibrillation by ablation | |
| NO20070148L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
| JP2007527904A5 (enExample) | ||
| JP2011068661A (ja) | 洞房結節Ｉｆ電流阻害剤およびカルシウム阻害剤の新規な組み合わせならびにそれを含む医薬組成物 | |
| ES2296964T3 (es) | Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares. | |
| NO20070147L (no) | Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen | |
| WO2009114716A3 (en) | Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling | |
| MY138896A (en) | Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom | |
| Atlee | Cardiac arrhythmias: drugs and devices | |
| JP2007527903A5 (enExample) | ||
| RU2005119970A (ru) | Оптически активное производное дигидропиридина | |
| US20150313872A1 (en) | Combination of a slow sodium current blocker and a sinus if current inhibitor, and the pharmaceutical compositions containing said combination | |
| Ono et al. | KB-R9032, newly developed Na+/H+ exchange inhibitor, attenuates reperfusion-induced arrhythmias in isolated perfused rat heart | |
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |